REGENXBIO licenses RGX-121/RGX-111 to Nippon Shinyaku for $110M upfront, up to $700M milestones

REGENXBIO Inc.

Upfront $110M, milestones up to $700M ($40M dev/reg, $660M sales), plus double-digit royalties on net sales in U.S. and Asia.
REGENXBIO retains 100% of proceeds from RGX-121 Priority Review Voucher; rolling BLA submitted, potential FDA approval late 2025.
Nippon Shinyaku to commercialize in Licensed Territory (U.S., Asia); REGENXBIO leads manufacturing and retains rest-of-world rights.
RGX-111 for MPS I (Hurler) also included; Phase 1/2 results promising. Deal expected to close by end of Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.